Etemadi Jalal, Shoja Mohammadali M, Ghabili Kamyar, Talebi Mahnaz, Namdar Hossein, Mirnour Reshad
Medical Philosophy and History Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
J Med Case Rep. 2011 Oct 27;5:530. doi: 10.1186/1752-1947-5-530.
Neurological complications leading to morbidity and mortality are not frequent in renal transplant recipients. Here, we report a renal transplant recipient who presented with diminished strength in his limbs probably due to multiple etiologies of axonal sensorimotor polyneuropathy, which resolved with intravenous immunoglobulin.
A 49-year-old Iranian male renal transplant recipient with previous history of autosomal dominant polycystic kidney disease presented with diminished strength in his limbs one month after surgery. Our patient was on cyclosporine A, mycophenolate mofetil and prednisone. Although a detected hypophosphatemia was corrected with supplemental phosphate, the loss of strength was still slowly progressive and diffuse muscular atrophy was remarkable in his trunk, upper limb and pelvic girdle. Meanwhile, his cranial nerves were intact. Post-transplant diabetes mellitus was diagnosed and insulin therapy was initiated. In addition, as a high serum cyclosporine level was detected, the dose of cyclosporine was reduced. Our patient was also put on intravenous ganciclovir due to positive serum cytomegalovirus immunoglobulin M antibody. Despite the reduction of oral cyclosporine dose along with medical therapy for the cytomegalovirus infection and diabetes mellitus, his muscular weakness and atrophy did not improve. One week after administration of intravenous immunoglobulin, a significant improvement was noted in his muscular weakness.
A remarkable response to intravenous immunoglobulin is compatible with an immunological basis for the present condition (post-transplant polyneuropathy). In cases of post-transplant polyneuropathy with a high clinical suspicion of immunological origin, administration of intravenous immunoglobulin may be recommended.
导致发病和死亡的神经系统并发症在肾移植受者中并不常见。在此,我们报告一名肾移植受者,其四肢力量减弱可能是由于轴索性感觉运动性多发性神经病的多种病因所致,经静脉注射免疫球蛋白后症状得到缓解。
一名49岁的伊朗男性肾移植受者,既往有常染色体显性多囊肾病病史,术后1个月出现四肢力量减弱。我们的患者正在服用环孢素A、霉酚酸酯和泼尼松。尽管检测到的低磷血症通过补充磷酸盐得到了纠正,但力量丧失仍在缓慢进展,其躯干、上肢和骨盆带出现明显的肌肉萎缩。同时,他的颅神经完好无损(正常)。诊断为移植后糖尿病并开始胰岛素治疗。此外,由于检测到血清环孢素水平较高,降低了环孢素的剂量。由于血清巨细胞病毒免疫球蛋白M抗体呈阳性,我们的患者还接受了静脉注射更昔洛韦治疗。尽管降低了口服环孢素的剂量,并对巨细胞病毒感染和糖尿病进行了药物治疗,但他的肌肉无力和萎缩并未改善。静脉注射免疫球蛋白1周后,其肌肉无力有了显著改善。
对静脉注射免疫球蛋白的显著反应与当前病情(移植后多发性神经病)的免疫基础相符。对于高度怀疑免疫起源的移植后多发性神经病病例,可建议使用静脉注射免疫球蛋白。